Crossject Société Anonyme (EPA:ALCJ)

Market Cap	113.79M +39.6%
Revenue (ttm)	2.57M -37.6%
Net Income	-10.37M
EPS	-0.20
Shares Out	54.44M
PE Ratio	n/a
Forward PE	5.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	723,798
Open	2.000
Previous Close	2.090
Day's Range	1.948 - 2.050
52-Week Range	1.346 - 2.695
Beta	0.46
Analysts	Strong Buy
Price Target	4.40 (+123.12%)
Earnings Date	Jun 24, 2026

About Crossject Société Anonyme

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is dev...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2001
• Employees: 99
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCJ

Financial Performance

In 2025, Crossject Société Anonyme's revenue was 2.57 million, a decrease of -37.59% compared to the previous year's 4.12 million. Losses were -10.37 million, -18.97% less than in 2024.